C2 -CORVUS Cholesterol-Control (C2) Controlled Targets for High Vascular Risk Patients Using Effective Statins (CORVUS) (C2 -CORVUS)

December 3, 2009 updated by: AstraZeneca
To demonstrate a higher percent rate of achieved target lipid goals among patients at high cardiovascular risk using more potent lipid-lowering treatment options including high-potency statins and combination therapies.

Study Overview

Status

Completed

Conditions

Study Type

Observational

Enrollment (Anticipated)

1500

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Hungary
      • Baja, Hungary
        • Research Site
      • Bekescsaba, Hungary
        • Research Site
      • Budapest, Hungary
        • Research Site
      • Budapest Iii District, Hungary
        • Research Site
      • Cegled, Hungary
        • Research Site
      • Debrecen, Hungary
        • Research Site
      • Gyongyos, Hungary
        • Research Site
      • Gyula, Hungary
        • Research Site
      • Jaszbereny, Hungary
        • Research Site
      • Kalocsa, Hungary
        • Research Site
      • Karcag, Hungary
        • Research Site
      • Kecskemet, Hungary
        • Research Site
      • Kisvarda, Hungary
        • Research Site
      • Mohacs, Hungary
        • Research Site
      • Nyiregyhaza, Hungary
        • Research Site
      • Oroshaza, Hungary
        • Research Site
      • Paszto, Hungary
        • Research Site
      • Puspokladany, Hungary
        • Research Site
      • Salgotarjan, Hungary
        • Research Site
      • Szarvas, Hungary
        • Research Site
      • Szecseny, Hungary
        • Research Site
      • Szekesfehervar, Hungary
        • Research Site
      • Szekszard, Hungary
        • Research Site
      • Szolnok, Hungary
        • Research Site
      • Tatabanya, Hungary
        • Research Site
      • Vac, Hungary
        • Research Site

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

Ambulatory clinics

Description

Inclusion Criteria:

  • Patients at high cardiovascular risk according to Framingham or SCORE rates

Exclusion Criteria:

  • Not eligible for lipid or statin therapy
  • Intolerance to therapy
  • Patients at low or intermediate CV risk

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Prospective

Cohorts and Interventions

Group / Cohort
Patients at high cardiovascular risk

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Percent rate of patients achieving target LDL cholesterol goals
Time Frame: On each of the 3 visits performed during the study
On each of the 3 visits performed during the study
Percent rate of patients achieving 50% or more reduction in LDL-cholesterol
Time Frame: On each of the 3 visits performed during the study
On each of the 3 visits performed during the study

Secondary Outcome Measures

Outcome Measure
Time Frame
Percent rate of patients achieving target secondary (total Ch, triglycerides, HDL Ch) goals
Time Frame: On each of the 3 visits performed during the study
On each of the 3 visits performed during the study
Percent rate of compliance among patients in the study
Time Frame: On each of the 3 visits performed during the study
On each of the 3 visits performed during the study

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

AstraZeneca

Investigators

  • Principal Investigator: Mark Laszlo, MD, PHD, County Hospital Bekes, Gyula
  • Study Director: Csaba Csongvai, MD, AstraZeneca Hungary

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

May 1, 2009

Study Completion (Actual)

November 1, 2009

Study Registration Dates

First Submitted

June 12, 2009

First Submitted That Met QC Criteria

June 15, 2009

First Posted (Estimate)

June 16, 2009

Study Record Updates

Last Update Posted (Estimate)

December 4, 2009

Last Update Submitted That Met QC Criteria

December 3, 2009

Last Verified

December 1, 2009

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • NIS-CHU-DUM-2009/1

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cardiovascular Risk

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Netherlands

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe